Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesWound CarePremera Bluecross NPWT Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 1.01.508

    Negative Pressure Wound Therapy (NPWT) Devices

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 1.01.508 alerts

    Get alerted when Policy 1.01.508 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when powered and single-use negative pressure wound therapy devices may be considered medically necessary, investigational, or not medically necessary, primarily for outpatient wound care. It applies to providers requesting initial therapy or continuation authorization for adults and adolescents aged 12 years and older.

    Policy Summary
    PayerPremera Bluecross
    PolicyNegative Pressure Wound Therapy (NPWT) Devices
    Policy CodePolicy 1.01.508
    Change TypeModified
    Effective DateSeptember 4, 2026
    Last ReviewMay 12, 2026
    Next Review DateN/A
    Key ActionFor continuation after the initial two-week trial, document objective wound improvement, including healthy granulation tissue, progressive wound contracture, and epithelial spread from the wound margins.
    SourceLink
    POLICY UPDATE CHANGES

    The policy no longer states that it applies only to adults aged 19 years and older.

    Use of NPWT systems is considered investigational for individuals aged 11 years and younger.

    The policy's consideration of the age statement was updated in the current interim review.

    The documentation section requesting the wound evaluation location, specific DME, and wound measurements was deleted.

    HCPCS code A9272 was added to the policy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 weeksInitial therapeutic trial
    30 daysInitial authorization
    30 daysContinuation authorization
    Objective healingContinuation evidence
    ≤11 yearsInvestigational age

    Medical Necessity and Coverage Criteria

    Initial powered NPWT therapy

    An initial powered NPWT therapeutic trial may be considered medically necessary when all general requirements and at least one qualifying indication are met.

    General initiation requirements

    • Qualifying indication

      • Stage III or IV pressure ulcer: The patient has a chronic stage III or IV pressure ulcer present for more than 90 days that has failed to heal despite optimal wound care, with high-volume drainage that interferes with healing and/or inability to maintain standard dressings because of anatomic factors.More than 90 days; exudate exceeding 150–200 mL/day when applicable
      • Nonhealing wound with an adverse clinical condition: The wound has remained nonhealing for at least 30 days despite optimal wound care, and the patient has an underlying condition known to negatively affect wound healing, such as diabetes, malnutrition, small vessel disease, or morbid obesity.At least 30 days; BMI ≥40 kg/m² for qualifying morbid obesity

        Malnutrition must be addressed simultaneously with NPWT.

      • Traumatic or surgical wound: A traumatic or surgical wound has failed immediate or delayed primary closure and contains exposed bone, cartilage, tendon, or foreign material.Failed closure plus exposed qualifying structure or material

    Continuation therapy

    Continuation of powered NPWT may be considered medically necessary after the initial 2-week trial when all continuation requirements are met.

    Continuation requirements

    • Objective wound improvement: The wound demonstrates healthy granulation tissue, progressive wound contracture with decreasing depth, and commencement of epithelial spread from the wound margins.All three findings

    Not medically necessary continuation

    Continuation is not medically necessary when any one of the following conditions occurs.

    Continuation denial conditions: The therapeutic trial or subsequent treatment period has not produced documented objective wound improvement; wound complications contraindicate continued NPWT; or the wound has healed sufficiently for grafting or is expected to heal completely with other wound care.Any one condition

    Investigational NPWT

    The following uses are investigational.

    Investigational uses: Use of a single-use NPWT system, whether powered or nonpowered, or use of an NPWT system in an individual aged 11 years or younger.Age ≤11 years

    The policy identifies FDA approval for adolescents and adults aged 12 years and older.

    Initial therapeutic trial

    A therapeutic trial of NPWT may be considered medically necessary when at least one qualifying wound and treatment-history pathway is met.

    Qualifying wound and treatment history

    • Chronic wound pathway: The chronic wound has failed to heal despite intensive conventional wound therapy for at least 90 days.At least 90 days
    • High-risk nonhealing wound pathway: The wound has been present for at least 30 days and has a high probability of failure to heal because of compounding factors involving the wound and the patient.At least 30 days
    • Traumatic or surgical wound pathway: The traumatic or surgical wound has failed to close and contains exposed bone, cartilage, tendon, or foreign material.

    Continuation therapy

    Continuation beyond the initial therapeutic trial requires objective evidence of wound healing.

    Continuation criteria

    • Objective healing evidence: The wound demonstrates development of healthy granulation tissue or progressive wound contracture.

    Diabetic foot ulcers

    NICE guidance recommends considering NPWT after surgical debridement for diabetic foot ulcers on the advice of a multidisciplinary foot care service.

    Diabetic foot ulcer guidance: Consider NPWT after surgical debridement when advised by the multidisciplinary foot care service.

    The cited evidence was limited and of low quality; this is guideline guidance rather than an explicit Premera coverage criterion.

    Pressure ulcers

    NICE guidance does not recommend routine NPWT for pressure ulcers.

    Pressure ulcer use: NPWT may be considered when necessary to reduce the number of dressing changes, such as for a wound with a large amount of exudate.

    This is guideline guidance rather than an explicit Premera coverage criterion.

    Cesarean delivery

    NICE guidance recommends considering NPWT after cesarean birth for selected patients.

    Cesarean delivery: Consider NPWT for women with a body mass index of at least 35 kg/m² to reduce the risk of wound infection; routine use following cesarean delivery is not recommended.BMI ≥35 kg/m²

    This is guideline guidance rather than an explicit Premera coverage criterion.

    NPWT is contraindicated when the wound contains necrotic tissue with eschar, untreated osteomyelitis, a nonenteric or unexplored fistula, malignancy, an exposed nerve, an exposed anastomotic site, or an exposed organ. These wound conditions must be evaluated before therapy is initiated or continued.

    Therapeutic trials of powered NPWT for acute or chronic wounds that do not meet the policy’s powered NPWT initiation criteria are not medically necessary.

    No NPWT device has been FDA cleared for use in neonates, infants, or children. NPWT use in these age groups may therefore be denied because safety and effectiveness have not been established for these populations.

    The 2023 IWGDF/IDSA guideline suggests not using NPWT, with or without instillation, to address diabetic foot infections. This is a conditional recommendation supported by low-quality evidence.

    NICE guidance reports that the V.A.C. Veraflo Therapy system shows promise for acute infected or chronic non-healing wounds, but there is insufficient high-quality evidence to support routine adoption. The guidance recommends randomized controlled research comparing V.A.C. Veraflo Therapy with NPWT alone.

    Continuation of powered NPWT is not medically necessary when the initial trial or a subsequent treatment period does not produce documented objective wound improvement, when a wound complication contraindicates continued NPWT, or when the wound has healed sufficiently for grafting or is expected to heal completely with other wound-care treatment.

    Input from physician specialty societies and academic medical centers was generally supportive of NPWT trials for chronic pressure ulcers that failed to heal, traumatic or surgical wounds that failed to close with exposed bone, cartilage, tendon, or foreign material, and nonhealing wounds associated with conditions that impair healing. The input generally considered trials for other acute or chronic wounds not medically necessary.

    Coding and Thresholds

    CPT CodesCPT
    97605Negative pressure wound therapy (e.g., vacuum-assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters
    97606Negative pressure wound therapy (e.g., vacuum-assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters
    97607Negative pressure wound therapy (e.g. vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters
    97608Negative pressure wound therapy (e.g. vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters
    HCPCS CodesHCPCS
    E2402Negative pressure wound therapy electrical pump, stationary or portable
    K0743Suction pump, home model, portable, for use on wounds
    K0744Absorptive wound dressing for use with suction pump, home model, portable, pad size 16 sq in or less
    K0745Absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 sq in but less than or equal to 48 sq in
    K0746Absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 sq in
    FDA device and product codesmixed
    K081406FDA 510(k) clearance pathway identifier for the SNaP Wound Care System
    K103156FDA 510(k) clearance pathway identifier for the V.A.C. VERAFLO Therapy device
    K161418FDA 510(k) clearance pathway identifier for Simultaneous Irrigation Technology tubing sets
    OMPFDA product code for negative pressure wound therapy devices
    HCPCS code referenced in policy historyHCPCS
    A9272
    High-volume drainage
    DefinitionExudate exceeding 150–200 mL/day
    Clinical effectOverwhelms NPWT dressings
    Treatment impactBreaks seal integrity and hinders healing
    Morbid obesity
    BMI thresholdBMI ≥40 kg/m²
    Clinical contextMorbid obesity is considered when it negatively affects NPWT

    Authorization and Documentation Requirements

    Prior Authorization

    30-Day Initial and Continuation Authorization

    Request authorization for an initial powered NPWT therapeutic trial for up to 30 days. Re-authorization for continuation may be approved for an additional 30 days when documented objective wound improvement is present.

    • Initial authorization: 30 days.
    • Re-authorization: another 30 days with documented objective improvement.
    Step Therapy

    Therapeutic Trial Eligibility

    A therapeutic trial of powered NPWT may be medically necessary when it is part of a comprehensive wound-care program and meets the policy's wound-history, failed-care, risk-factor, or qualifying-wound requirements. The trial must be at least 14 days.

    • Minimum therapeutic-trial duration: 14 days.
    • Eligible circumstances include chronic wounds that failed intense conventional wound therapy for at least 90 days, or wounds present at least 30 days with a high probability of failure to heal because of compounding wound or patient factors.

    Therapy Background

    Negative pressure wound therapy (NPWT) applies suction to the wound bed to remove fluid, debris, and infectious material and to promote granulation tissue formation and healing. Powered systems are intended for use within a comprehensive wound-care program that also addresses factors such as diabetes control, nutritional status, and pressure relief. The policy identifies risks associated with NPWT, including bleeding and infection, particularly during dressing changes, and calls for frequent monitoring by trained practitioners.

    A nonpowered (mechanical) NPWT system is a portable, disposable system consisting of a cartridge, dressing, and strap, with the cartridge serving as the negative-pressure source. The policy distinguishes these single-use systems from powered NPWT; single-use NPWT systems, whether powered or nonpowered, are considered investigational under the stated coverage criteria.

    Definitions

    High-volume drainage
    DefinitionExudate exceeding 150–200 mL/day
    Dressing impactOverwhelms NPWT dressings
    Healing impactBreaks seal integrity and hinders healing
    Small vessel disease
    DefinitionMicrovascular damage
    Perfusion effectRestricts perfusion
    NPWT effectImpairs NPWT effectiveness
    Policy Summary
    PayerPremera Bluecross
    PolicyNegative Pressure Wound Therapy (NPWT) Devices
    Policy CodePolicy 1.01.508
    Change TypeModified
    Effective DateSeptember 4, 2026
    Last ReviewMay 12, 2026
    Next Review DateN/A
    Key ActionFor continuation after the initial two-week trial, document objective wound improvement, including healthy granulation tissue, progressive wound contracture, and epithelial spread from the wound margins.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and ThresholdsAuthorization and Documentation RequirementsTherapy BackgroundDefinitions
    Underlying-condition pathway: The wound is nonhealing and the patient has an underlying clinical condition known to negatively affect wound healing.
    Wound-healing relevance
    An underlying condition known to negatively impact wound healing
    CPT 97605 and 97607
    CPT codes97605 and 97607
    Wound surface areaLess than or equal to 50 square centimeters
    Billing basisTotal wound(s) surface area per session
    CPT 97606 and 97608
    CPT codes97606 and 97608
    Wound surface areaGreater than 50 square centimeters
    Billing basisTotal wound(s) surface area per session
    Prior intensive conventional wound therapy
    Minimum durationAt least 90 days
    Treatment typeIntensive conventional wound therapy
    Eligibility contextThe chronic wound must have failed to heal despite this therapy
    Wound duration with high-risk compounding factors
    Minimum wound durationAt least 30 days
    Risk requirementHigh probability of failure to heal
    Contributing factorsCompounding factors involving the wound and the patient
    Therapeutic NPWT trial
    Minimum trial durationNot less than 14 days
    TherapyNegative pressure wound therapy
    PurposeTherapeutic trial for qualifying problematic wounds
    Continuation beyond initial NPWT trial
    Continuation thresholdBeyond 14 days
    Required evidenceObjective evidence of wound healing
    ExamplesDevelopment of healthy granulation tissue or progressive wound contracture
    NPWT after cesarean birth
    BMI thresholdBMI ≥35 kg/m²
    Clinical settingAfter cesarean birth
    Guideline purposeConsider NPWT to reduce the risk of wound infections; routine use is not recommended
    Documentation Required

    Concurrent Malnutrition Treatment

    Document that malnutrition is being treated concurrently when it is a clinical condition affecting wound healing and is cited to support NPWT.

    • Malnutrition must have treatment documented as occurring simultaneously with NPWT.
    Documentation Required

    General Clinical Records

    For the initial two-week powered-NPWT trial, submit office visit notes with the relevant history and physical and records supporting the medical-necessity indication, prior wound care, and requested treatment.

    • Document the qualifying indication and why powered NPWT is required.
    • Include prior or ongoing wound-care treatment and the planned initial-trial details.
    Documentation Required

    Initial Trial Documentation

    Initial-trial documentation must establish a qualifying indication and explain why powered NPWT is required as part of comprehensive wound care.

    • Stage III or IV pressure ulcer present for more than 90 days and failed to heal despite optimal wound care.
    • High-volume drainage that interferes with healing and/or inability to maintain standard dressings because of anatomic factors.
    • Nonhealing wound present for at least 30 days despite optimal wound care in a patient with diabetes, malnutrition, small-vessel disease, morbid obesity, or another documented compounding factor.
    • Traumatic or surgical wound after failure of immediate or delayed primary closure.
    • Exposed bone, cartilage, tendon, or foreign material within the wound.
    Documentation Required

    Continuation Response Documentation

    For continuation after the initial two-week trial, document that the wound has shown objective improvement and that improvement continues during subsequent treatment.

    • Objective improvement includes healthy granulation tissue, progressive wound contracture with decreasing depth, and commencement of epithelial spread from the wound margins.
    • Healing must be monitored at intervals of no more than 14 days.
    Documentation Required

    Wound History and Failed Conventional Care

    Document the wound's duration, prior conventional treatment, response to that treatment, and patient or wound factors that increase the probability of failed healing.

    • Chronic wounds must have failed intense conventional wound therapy for at least 90 days.
    • Wounds of at least 30 days must have documented compounding factors or clinical conditions associated with impaired healing.
    • NPWT is a second-line or adjunctive intervention after appropriate conservative or first-line therapy has not produced healing.
    Documentation Required

    Objective Response for Continued Therapy

    For therapy beyond 14 days, provide objective evidence of healing rather than relying only on continued wound presence or subjective improvement.

    • Document healthy granulation tissue.
    • Document progressive wound contracture with decreasing depth.
    • Document commencement of epithelial spread from the wound margins.
    • Monitor and record healing at least every 14 days.
    Documentation Required

    Qualifying Wound Characteristics

    The wound must have characteristics supporting a qualifying NPWT indication, including a nonhealing course or failure of closure and, where applicable, exposed structures or material.

    • Exposed bone, cartilage, tendon, or foreign material within the wound.
    • Traumatic or surgical wound with failure of immediate or delayed primary closure.
    • Nonhealing wound of at least 30 days despite optimal wound care when supported by a condition known to impair healing.
    Denial Risk

    Failure to Demonstrate Continued Improvement

    Continuation is not medically necessary when the initial trial or subsequent treatment has not produced documented objective improvement, when a complication contraindicates continued NPWT, or when the wound has healed sufficiently for grafting or expected healing with other wound care.

    • Do not continue without documented objective improvement.
    • Stop or reassess when a wound complication contraindicates continued NPWT.
    • Continuation is not necessary when grafting can be performed or complete healing is anticipated with other wound-care treatment.
    Denial Risk

    Wound Does Not Meet Initiation Criteria

    Therapeutic trials for acute or chronic wounds that do not satisfy the policy's initiation criteria are considered not medically necessary.

    • A wound that lacks a qualifying duration, failed-care history, compounding factor, closure failure, or qualifying exposed structure does not meet initiation criteria.
    Denial Risk

    Investigational Device or Age

    Single-use NPWT systems, whether powered or nonpowered, are investigational. NPWT is also investigational for individuals aged 11 years and under.

    • Single-use NPWT systems: CPT 97607 and 97608.
    • Age criterion: investigational for individuals 11 years and under; FDA-approved use is for adolescents and adults aged 12 years and older.
    Denial Risk

    Contraindicated Wound Condition

    Do not use NPWT for contraindicated wound conditions identified in the FDA safety alerts unless the condition has been appropriately addressed and the treating clinician determines use is safe.

    • Necrotic tissue with eschar.
    • Untreated osteomyelitis.
    • Nonenteric or unexplored fistulae.
    • Malignancy in the wound.
    • Exposed nerve, anastomotic site, or organ.
    • Select patients carefully, monitor frequently in an appropriate setting, and remain vigilant for bleeding, infection, and other serious complications.
    Denial Risk

    No Objective Improvement for Continuation

    Continuation requires objective healing evidence beyond the initial 14-day trial. Without such evidence, continued powered NPWT is not medically necessary.

    • Document healthy granulation tissue, progressive wound contracture with decreasing depth, and/or epithelial spread from the wound margins.
    • Reassess healing at least every 14 days.
    Denial Risk

    Insufficient Wound History or Risk Factors

    Requests may be denied when the record does not establish the required wound duration, failed conventional care, or patient or wound factors that increase the risk of nonhealing.

    • Document at least 90 days of failed intense conventional therapy for qualifying chronic wounds.
    • Alternatively, document a wound present at least 30 days with a high probability of failure to heal because of compounding factors.
    • Include the specific prior therapies, outcomes, and relevant risk factors.
    Denial Risk

    Unsupported Wound Indication

    Therapeutic trials for other acute or chronic wounds that do not meet the policy's qualifying criteria are considered not medically necessary.

    • Unsupported indications include wounds without the required failed-care history, duration, closure failure, exposed structure, or documented healing-risk factor.
    Denial Risk

    Pediatric Use Lacks FDA Clearance

    NPWT is not FDA cleared for neonates, infants, or children. The policy states that NPWT systems are FDA approved only for adolescents and adults aged 12 years and older.

    • No NPWT device has FDA clearance for use in neonates, infants, or children.
    • Requests for pediatric use without applicable FDA clearance are subject to denial.
    Denial Risk

    Instillation System Not Indicated for Home Care

    Simultaneous Irrigation Technology tubing sets used with Cardinal Health SVED and PRO NPWT devices are not indicated for home-care use.

    • Instillation systems, including Simultaneous Irrigation Technology tubing sets, require an appropriate setting consistent with the device's clearance and labeling.
    • The V.A.C. VERAFLO system is commercially marketed for hospital use with the V.A.C. Ulta unit.
    Step Therapy

    Failure of Conservative Wound Care

    Use powered NPWT within a comprehensive wound-care program that addresses other factors affecting healing, including diabetes control, nutritional status, and pressure relief.

    • Document concurrent management of conditions that impair healing.
    • When malnutrition affects healing, document treatment simultaneous with NPWT.
    Morbid obesity affecting NPWT
    BMI thresholdBMI ≥40 kg/m²
    DefinitionMorbid obesity that negatively affects NPWT
    Clinical relevanceAn underlying condition known to negatively impact wound healing
    Stage III pressure ulcer
    Ulcer stageStage III pressure ulcer
    Skin involvementAffects the top two layers of skin
    Underlying tissueAlso affects fatty tissue
    Stage IV pressure ulcer
    Ulcer stageStage IV pressure ulcer
    DepthA deep pressure wound
    Tissue involvementMay impact muscle, tendons, ligaments, and bone
    Expected complete healing
    Covered structuresBone, cartilage, tendons, and foreign material are completely covered
    Granulation tissueHealthy granulation is present to within 5 mm of the surface
    Wound edgesReduced to 2 cm in width or diameter
    Negative pressure wound therapy
    DefinitionTherapy using negative pressure or suction
    Wound-bed actionAspirates and removes fluids, debris, and infectious materials
    Treatment goalPromotes granulation tissue formation and wound healing
    Nonpowered mechanical NPWT system
    System typePortable, disposable, nonpowered mechanical NPWT system
    ComponentsCartridge, dressing, and strap
    Pressure sourceThe cartridge serves as the negative pressure source
    Neonate
    Age groupNeonate
    Age rangeBirth to 28 days
    FDA classificationDefined by the FDA for NPWT-related regulatory considerations
    Infant
    Age groupInfant
    Age range29 days to less than 2 years
    FDA classificationDefined by the FDA for NPWT-related regulatory considerations
    Child
    Age groupChild
    Age range2 years to less than 12 years
    FDA classificationDefined by the FDA for NPWT-related regulatory considerations
    Closed incision negative pressure therapy
    DefinitionClosed incision negative pressure therapy used after surgery
    Pre-use assessmentEvaluate patient comorbidities before surgery
    Risk factorsConsider obesity, diabetes, and the nature of the surgery when assessing infection risk